November 29, 2022 02:45 PM EST
Law

A Supreme Court chill across biosim­i­lar 'skin­ny' la­bels could halt bil­lions in Medicare sav­ings

Zachary Brennan

Senior Editor

As gener­ic drug­mak­ers con­tin­ue to pe­ti­tion the US Supreme Court to pro­tect a long­stand­ing prece­dent that al­lows them to carve out and mar­ket cer­tain …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times